Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib acceptability and feasibility study in palmoplantar pustulosis
ISRCTN61751241Phase 4Completed
- Sponsor
- King's College London
- Start
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of upadacitinib in Palmoplantar Pustular Psoriasis (PPPP), sponsored by King's College London. Primary endpoints: Recruitment rate, Good adherence rate and 1 more. Started Nov 2024; status: completed.
02
Drugs
upadacitinib
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on ISRCTN61751241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN61751241.